

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
28 May 2009 (28.05.2009)

PCT

(10) International Publication Number  
WO 2009/067431 A2

- (51) International Patent Classification: A61L 31/10 (2006.01) A61L 31/16 (2006.01) [US/US]; 912 Chippewa Drive, Crown Point, IN 46307 (US).
- (21) International Application Number: PCT/US2008/083869
- (22) International Filing Date: 18 November 2008 (18.11.2008)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data: 60/989,263 20 November 2007 (20.11.2007) US
- (71) Applicants (for all designated States except US): **COOK INCORPORATED** [US/US]; 750 Daniels Way, Bloomington, IN 47404 (US). **MED INSTITUTE** [US/US]; 1 Geddes Way, West Lafayette, IN 47906 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): **LINDSAY, Ashley, P.** [US/US]; 3616 Mill Run Circle, Apt. 1618, Indianapolis, IN 46214 (US). **PEREZ-SEGARRA, Waleska** [US/US]; 253 Clearwater Drive, Kingsport, TN 37664 (US). **RU-ANE, Patrick, H.** [IE/US]; 1025 Park Place, Apt. 305, San Mateo, CA 94403 (US). **CASTERLINE, Christine**
- (74) Agent: **MARX, Jeffrey, A.**; Brinks Hofer Gilson & Lione, P.o. Box 10087, Chicago, IL 60610 (US).
- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published: — without international search report and to be republished upon receipt of that report

(54) Title: CONTROLLED DRUG DELIVERY USING A ZEIN LAYER MODIFIED WITH LEVULINIC ACID




Figure 1

(57) Abstract: The disclosure relates to medical devices coated with zein admixed with levulinic acid. The medical device may further include a therapeutic agent in contact with zein admixed with levulinic acid. Zein admixed with levulinic acid allows the therapeutic agent to be retained on the device during delivery and also controls the elution rate of the therapeutic agent following implantation. The disclosure further relates to methods of delivering a therapeutic agent on said medical devices as well as their use especially in the form of stents for prevention of restenosis.

WO 2009/067431 A2

**CONTROLLED DRUG DELIVERY USING A ZEIN LAYER MODIFIED WITH  
LEVULINIC ACID**

**INVENTORS:**

**ASHLEY P. LINDSAY**

5

**WALESKA PEREZ-SEGARRA**

**PATRICK H. RUANE**

**CHRISTINE CASTERLINE**

**PRIORITY CLAIM**

**[0001]** This application claims the benefit of provisional U.S. Patent  
10 Application Serial No. 60/989,263, filed November 20, 2007, which is  
incorporated herein by reference in its entirety.

**TECHNICAL FIELD**

**[0002]** The present disclosure relates to implantable medical devices and  
the controlled release of therapeutic agents therefrom. The disclosure relates  
15 particularly to the use of a zein layer admixed with levulinic acid to control the  
elution rate of at least one therapeutic agent. The disclosure further describes  
methods for the local administration of therapeutic agents to a target site.

**BACKGROUND OF THE DISCLOSURE**

**[0003]** Delivery of a therapeutic agent via an implantable device is  
20 desirable for a variety of applications. For example, therapeutic agents  
applied to an implantable device may treat or mitigate such undesirable  
conditions as restenosis, inflammation, tumor development, or thrombosis  
formation.

**[0004]** Procedures for mitigating such conditions may include implantation  
25 of a device comprising a therapeutic agent. For example, implantations of

stents during angioplasty procedures have substantially advanced the treatment of occluded blood vessels. Occasionally, angioplasty may be followed by an abrupt closure of the vessel or by a more gradual closure of the vessel, commonly known as "restenosis." Acute closure may result from  
5 an elastic rebound of the vessel wall and/or by the deposition of blood platelets and fibrin along a damaged length of the newly opened blood vessel. Restenosis may result from the natural healing reaction to the injury to the vessel wall (known as intimal hyperplasia), which involves the migration and proliferation of medial smooth muscle cells that continues until the vessel is  
10 again occluded.

**[0005]** To prevent such vessel occlusion, stents have been implanted within a body vessel. However, restenosis may still occur over the length of the stent and/or past the ends of the stent where the inward forces of the stenosis are unopposed. To reduce this problem, one or more therapeutic  
15 agents may be administered to the patient. For example, a therapeutic agent may be locally administered through a catheter positioned within the body vessel near the stent, or by coating the stent with the therapeutic agent.

**[0006]** Desirably, a medical device coated with a therapeutic agent is adapted to expose tissue within the body to the therapeutic agent over a  
20 desired time interval, such as by releasing the therapeutic agent. Desirably, the therapeutic agent is released within the body at a reproducible and predictable fashion so as to optimize the benefit of the therapeutic agent to the patient over the desired period of time. Providing coated medical devices adapted to release a therapeutic agent at a desired rate over a period of time  
25 is one challenge in designing implantable medical devices. For example, a coated medical device may release a therapeutic agent at a greater rate than desired upon implantation, and subsequently release the therapeutic agent at a slower rate than desired at some time after implantation.

**[0007]** The design configuration of an implantable device can be adapted  
30 to control the release of therapeutic agent from the device. For example, a therapeutic agent can be included in the implantable medical device, such as

an implantable frame comprising a porous biostable material optionally mixed with or coated on top of a therapeutic agent. Current Drug Eluting Stents (DES) may incorporate permanent biostable polymers into their coatings. For example, U.S. Patent Applications 2005/0176678 and 2005/0060028 describe  
5 polymeric bioabsorbable coatings including polylactic acid and polyglycolic acid. However, there is some concern that these permanent polymers may lead to late thrombosis. It has been shown that various bioabsorbable polymers may produce an excess tissue response (*Heart*. 1998 Apr; 79(4):319-23). Implanted polymer coatings have been associated with a  
10 significant inflammatory and exaggerated neointimal proliferative response, as well as enhanced thrombotic response (*Circulation*. 1996; 94(7):1494-5).

**[0008]** As a consequence, there has been interest in recent years in developing alternative coating configurations that do not require durable polymers, but include a bioabsorbable material. Naturally occurring  
15 bioabsorbable coatings with improved biocompatibility are desirable. One suitable naturally-derived material is corn-derived proteins called zeins that constitute most of the storage proteins of maize seed. During development of the kernel, zein accretions form in the peripheral regions of the lumen of the rough endoplasmic reticulum. These ultimately develop into cytoplasmic  
20 deposits called vesicular protein bodies ranging in size from 1 to 3  $\mu\text{m}$  in diameter. At maturity, zein comprises more than half of all extractable proteins found in the maize endosperm. Human liver cells and mouse fibroblast cells have been shown to attach to and proliferate on zein, suggesting that zein may be biocompatible. J. Dong et al., "Basic study of  
25 corn protein, zein, as a biomaterial in tissue engineering, surface morphology and biocompatibility," *Biomaterials* 25, 4691-4697 (2004). Further, Wang et al. describe a cardiovascular device coating comprising zein microspheres and heparin. H-J. Wang et al., "Heparin-loaded zein microsphere film and hemocompatibility," *Journal of Controlled Release* 105, 120-131 (2005).

30 **[0009]** However, zein coatings may be dry and brittle. There is some concern this characteristic may lead to tearing and cracks appearing in a zein

coating, especially when the zein coating is thin. Further, an implantable device may be subjected to mechanical straining (e.g., crimping, loading into a delivery device, sterilizing) that may introduce cracks and peeling in a zein coating on the device.

5

## SUMMARY

**[0010]** In one aspect, a medical device comprising a frame and a coating is provided. The coating comprises zein admixed with levulinic acid. The coating may further comprise therapeutic agent.

10 **[0011]** In another aspect, a medical device comprising a frame and a coating is provided. The coating comprises at least two layers. The first layer comprises a therapeutic agent. The second layer comprises zein or modified zein admixed with levulinic acid, and the second layer at least partially covers the first layer.

15 **[0012]** In a further aspect, a medical device comprising a frame and a coating is provided. The coating comprises about 1:1 to about 1:20 weight ratio of a taxane therapeutic agent to zein or modified zein admixed with levulinic acid.

20 **[0013]** In operation, one can deliver a therapeutic agent to a patient in need thereof by introducing a medical device in accordance with the present disclosure, wherein the medical device comprises at least one therapeutic agent and zein admixed with levulinic acid with a ratio of about 1:1 to about 1:20 by weight of the at least one therapeutic agent to zein admixed with levulinic acid.

25 **[0014]** Other systems, methods, features and advantages will be, or will become, apparent to one with skill in the art upon examination of the following figures and detailed description. It is intended that all such additional systems, methods, features and advantages be included within this description, be within the scope of the disclosure, and be protected by the following claims.

### BRIEF DESCRIPTION OF THE DRAWINGS

**[0015]** The medical device may be better understood with reference to the following drawings and description. The components in the figures are not necessarily to scale, emphasis instead being placed upon illustrating the principles of the disclosure. Moreover, in the figures, like referenced

5 numerals designate corresponding parts throughout the different views.  
**[0016]** **Figure 1** is a schematic diagram showing a two-layer coating configuration according to one example.

**[0017]** **Figure 2** is a schematic drawing showing a multilayer coating

10 configuration according to one example.  
**[0018]** **Figures 3A, 3B, 3C and 3D** are SEM images of a Zilver® stent coated with paclitaxel and zein admixed with levulinic acid.

**[0019]** **Figure 4** is an SEM image of a paclitaxel-zein coated Zilver® stent.

**[0020]** **Figure 5** shows the elution profile of a medical device coated with

15 only paclitaxel  
**[0021]** **Figure 6** shows an elution profile for one example in heptakis(2, 6-dr-O-methyl)- $\beta$ -cyclodextrin (“HCD”).

**[0022]** **Figure 7** shows the percent of paclitaxel eluted over four hours in an HCD solution as a function of the ratio of paclitaxel to zein admixed with

20 levulinic acid.

### DETAILED DESCRIPTION

**[0023]** The present disclosure provides for a medical device coated with zein admixed with levulinic acid (“zein/levulinic acid”). The medical device may be configured to release a therapeutic agent from the medical device

25 where the coating further includes a therapeutic agent in contact with the layer of zein/levulinic acid. The rate of release of the therapeutic agent may be influenced by the composition and structure of the medical device. The medical device may optionally include one or more bioabsorbable materials, biostable materials, or any combination thereof. Desirably, the medical device

comprises materials configured to provide for the release of one or more therapeutic agents within a body lumen according to a therapeutically effective release profile.

**[0024]** Unless otherwise defined, all technical and scientific terms used  
5 herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure pertains. In case of conflict, the present document, including definitions, will control. Preferred methods and materials are described below, although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present  
10 disclosure. All publications, patent applications, patents and other references mentioned herein are incorporated by reference in their entirety. The materials, methods, and examples disclosed herein are illustrative only and not intended to be limiting.

15 Definitions

**[0025]** As used herein, the term "body vessel" means any tube-shaped body passage lumen that conducts fluid, including but not limited to blood vessels such as those of the human vasculature system, esophageal, intestinal, biliary, urethral and ureteral passages.

20 **[0026]** The term "biocompatible" refers to a material that is substantially non-toxic in the in vivo environment of its intended use, and that is not substantially rejected by the patient's physiological system (i.e., is non-antigenic). This can be gauged by the ability of a material to pass the biocompatibility tests set forth in International Standards Organization (ISO)  
25 Standard No. 10993 and/or the U.S. Pharmacopeia (USP) 23 and/or the U.S. Food and Drug Administration (FDA) blue book memorandum No. G95-1, entitled "Use of International Standard ISO-10993, Biological Evaluation of Medical Devices Part 1: Evaluation and Testing." Typically, these tests measure a material's toxicity, infectivity, pyrogenicity, irritation potential,  
30 reactivity, hemolytic activity, carcinogenicity and/or immunogenicity. A biocompatible structure or material, when introduced into a majority of

patients, will not cause a significantly adverse, long-lived or escalating biological reaction or response, and is distinguished from a mild, transient inflammation which typically accompanies surgery or implantation of foreign objects into a living organism.

5 **[0027]** The term “hydrophobic” refers to material that tends not to interact with water. One way of observing hydrophobicity is to observe the contact angle formed between a water droplet or solvent and a substrate; the higher the contact angle the more hydrophobic the surface. Generally, if the contact angle of a liquid on a substrate is greater than 90° then the material is said to  
10 be hydrophobic.

**[0028]** The term “implantable” refers to an ability of a medical device to be positioned, for any duration of time, at a location within a body, such as within a body vessel. Furthermore, the terms “implantation” and “implanted” refer to the positioning, for any duration of time, of a medical device at a location  
15 within a body, such as within a body vessel.

**[0029]** The term “interconnecting surface” refers to the surface of a medical device connecting a medical device abluminal surface to a medical device luminal surface.

**[0030]** The phrase “controlled release” refers to an adjustment in the rate  
20 of release of a therapeutic agent from a medical device in a given environment. The rate of a controlled release of a therapeutic agent may be constant or vary with time. A controlled release may be characterized by a drug elution profile, which shows the measured rate at which the therapeutic agent is removed from a drug-coated device in a given solvent environment  
25 as a function of time.

**[0031]** The phrase “therapeutic agent” refers to any pharmaceutically active agent that results in an intended therapeutic effect on the body to treat or prevent conditions or diseases. Therapeutic agents include any suitable biologically active chemical compounds, biologically derived components such  
30 as cells, peptides, antibodies, and polynucleotides, and radiochemical therapeutic agents, such as radioisotopes.

**[0032]** An "anti-proliferative" agent/factor/drug indicates any protein, peptide, chemical or other molecule that acts to inhibit cell proliferative events. Examples of anti-proliferative agents include microtubule inhibitors such as vinblastine, vincristine, colchicine and paclitaxel, or other agents such as  
5 cisplatin.

**[0033]** The term "pharmaceutically acceptable," refers to those compounds of the present disclosure which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower mammals without undue toxicity, irritation, and allergic response, are  
10 commensurate with a reasonable benefit/risk ratio, and are effective for their intended use, as well as the zwitterionic forms, where possible, of the compounds of the disclosure.

**[0034]** The term "coating," unless otherwise indicated, refers generally to material attached to an implantable medical device prior to implantation. A  
15 coating can include material covering any portion of a medical device, and can include one or more coating layers. A coating can have a substantially constant or a varied thickness and composition. Coatings can be adhered to any portion of a medical device surface, including the luminal surface, the abluminal surface, or any portions or combinations thereof.

**[0035]** "Pharmaceutically acceptable salt" means those salts which are,  
20 within the scope of sound medical judgement, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response and the like, and are commensurate with a reasonable benefit/risk ratio. Pharmaceutically acceptable salts are well known in the art.  
25 For example, S.M. Berge et al., describe pharmaceutically acceptable salts in detail in J. Pharm Sciences, 66: 1-19 (1977), which is hereby incorporated by reference.

**[0036]** The term "pharmaceutically acceptable ester" refers to esters which hydrolyze in vivo and include those that break down readily in the human  
30 body to leave the parent compound or a salt thereof. Suitable ester groups include, for example, those derived from pharmaceutically acceptable

aliphatic carboxylic acids, particularly alkanolic, alkenolic, cycloalkanoic and alkanedioic acids, in which each alkyl or alkenyl moiety advantageously has not more than six carbon atoms. Examples of particular esters includes formates, acetates, propionates, butyates, acrylates and ethylsuccinates.

5 **[0037]** The term "pharmaceutically acceptable prodrug" refers to those prodrugs of the compounds of the present disclosure which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response, and the like, commensurate with a reasonable benefit/risk ratio, and effective for their intended use, as well as the zwitterionic forms, where possible, of the compounds of the disclosure. The term "prodrug" refers to compounds that are rapidly transformed in vivo to provide the parent compound having the above formula, for example by hydrolysis in blood. A thorough discussion is provided in T. Higuchi and V. Stella, Pro-drugs as  
10 Novel Delivery Systems, Vol. 14 of the A.C.S. Symposium Series, and in Edward B. Roche, ed., Bioreversible Carriers in Drug Design, American Pharmaceutical Association and Pergamon Press, 1987, both of which are incorporated herein by reference.

20 Zein

**[0038]** Zein may be obtained from any suitable source, but is preferably obtained from maize. Various methods and techniques exist for extracting zein from the maize endosperm. Laboratory preparation of zein, for example, involves extracting zein from maize endosperm with aqueous ethanol or  
25 isopropanol under mild conditions (such as an extraction temperature less than 10 degrees Celsius) with or without reducing agents. Commercial zein is typically extracted from corn gluten meal. For example, U.S. Patent Nos. 3,535,305; 5,367,055; 5,342,923; and 5,510,463 disclose extraction of zein from corn gluten using aqueous-alcohol solutions.

30 **[0039]** The study of zein reveals an extreme variability at the genetic level and consequently a complex situation amongst the zein proteins. Native zein

is actually a large, heterogeneous family of several groups of proteins that differ in molecular size, solubility, and charge. More than twenty different zein polypeptides have been estimated to exist. Analysis of zein extracts using high-performance liquid chromatography (HPLC), ion-exchange  
5 chromatography, gel exclusion chromatography, SDS-polyacrylamide gel electrophoresis (SDS-PAGE), isoelectric focusing (IEF), amino acid analysis, and DNA cloning techniques have led to a greatly improved understanding of zein proteins.

**[0040]** Amino acid composition analyses of zein disclose large amounts of  
10 leucine, alanine, glutamine, and phenylalanine; lysine and tryptophan are absent or present in very small amounts. The high proportion of non-polar amino acid residues and the exceptional lack of ionic groups are responsible for the highly hydrophobic nature of zein and for its unique solubility.

**[0041]** Zein protein bodies are composed of three structurally distinct types  
15 of proteins:  $\alpha$ -zein,  $\gamma$ -zein (which includes  $\beta$ -zein), and  $\delta$ -zein. These can be further differentiated into four classes ( $\alpha$ -,  $\beta$ -,  $\gamma$ -, and  $\delta$ -) on the basis of differences in solubility and sequence.

**[0042]** Zein extracted without reducing agents forms a large multigene  
20 family of polypeptides, termed  $\alpha$ -zein. Typically the most abundant fraction of native zein,  $\alpha$ -Zeins contain about 40 N-terminal amino acids that precede a series of nine or ten repeated peptides of 20 amino acids. These repeats are predicted to be  $\alpha$ -helical and wind the protein into a rod-shaped molecule.

**[0043]** The other fractions of zein ( $\beta$ -,  $\gamma$ -, and  $\delta$ - zein) must be extracted  
25 using aqueous alcohols containing reducing agents to break disulfide bonds. For example, mercaptoethanol is used for laboratory extraction.  $\beta$ -,  $\gamma$ -, and  $\delta$ -zein show no sequence homology with  $\alpha$ -zein.

**[0044]**  $\gamma$ -Zein is soluble in both aqueous and alcoholic solvents with  
reducing conditions. Each of the  $\gamma$ -zeins has a unique N-terminal sequence. For example, in the 50 kDa  $\gamma$ -zein, this region is 136 amino acids long and it is  
30 very H is rich. The 27 kDa  $\gamma$ -zein protein has a series of eight tandem hexapeptide repeats that occur 11 amino acids after the N-terminus. The first

eight amino acids of the 16 kDa  $\gamma$ -zein protein are identical to those of the 27 kDa  $\gamma$ -zein, but the 16 kDa  $\gamma$ -zein has three degenerate versions of Pro-rich repeat.  $\gamma$ -Zein typically comprises about 10 to 15% of total zein.

**[0045]**  $\beta$ -Zein, which is related to  $\gamma$ -zein, includes a methionine-rich polypeptide of 17 kDa and constitutes up to 10% of the total zein.

Approximately the last 140 amino acids of the  $\beta$ - and  $\gamma$ -zeins are 85% identical.  $\beta$ -Zein has no repetitive peptides and appears to consist of mostly  $\beta$ -sheet and turn conformation.

**[0046]**  $\delta$ -Zein is a 10 kDa protein and is a minor fraction of zein.  $\delta$ -Zeins are the most hydrophobic of the group, contain no repetitive peptides, and are exceptionally rich in Met and Cys.

**[0047]** Zein has been considered as Generally Recognized as Safe (G.R.A.S.) by the Food and Drug Administration since 1985 (CAS Reg. No. 9010-66-6). The source or grade of zein is not limited, and any zein can be used in the present disclosure. For example, commercial zeins that may be used in the present disclosure include, but are not limited to, Sigma-Aldrich product number Z 3625; Wako Pure Chemical Industries product numbers 261-00015, 264-01281, and 260-01283; Spectrum Chemical product numbers Z1131 and ZE105; ScienceLab stock keeping unit SLZ1150; SJZ Chem-Pharma Company product name ZEIN (GLIDZIN); Arco Organics catalog numbers 17931-0000, 17931-1000, and 17931-5000; and Freeman Industries zein regular grade F4000, zein regular grade F4400, zein special grade F6000, zein G10 film coating solution, zein G20 film coating solution, aqua zein, and aqua zein natural. Desirably, the commercial zein in the present disclosure is product number Z 3625, zein from maize, obtained from Sigma-Aldrich, St. Louis, MO.

**[0048]** The term "zein" as used herein includes native zein and modified zein. "Modified zein" includes zein proteins having an amino acid sequence which is not normally occurring, which behave similarly to authentic zeins, and which are soluble in alcohol. Amino acid substitutions, especially those which do not substantially modify the hydrophobicity, may be introduced. For

example, amino acid substitution within the repeated sections, single amino acid substitution, as well as substitutions in the segments connecting the domains of repeated sequences may be employed. Also, insertions and substitutions can be made in both the COOH- terminus and the NH<sub>2</sub> terminus of the zein molecule.

#### Levulinic Acid

**[0049]** Levulinic acid is a keto acid that is commonly used as a food additive, among other things. Common alternative chemical names for levulinic acid include 4-Oxopentanoic acid, 4-Oxovaleric acid, gamma-Ketovaleric acid, 4-Ketovaleric acid, Laevulinic acid,  $\beta$ -Acetylpropionic acid, propionic acid, keto acid, 3-acetyl-, and 3-Acetopropionic acid. As used herein, "levulinic acid" refers to levulinic acid and any derivatives thereof. For example, levulinic acid derivatives include, but are not limited to, methyltetrahydrofuran and esters of levulinic acid.

**[0050]** Levulinic acid has been considered as Generally Recognized as Safe (G.R.A.S.) by the Food and Drug Administration (CAS Reg. No. 123-76-2). The source or grade of levulinic is not limited, and any levulinic acid may be used in the present disclosure.

#### Coating Configurations For Controlled Release

**[0051]** In one example, the therapeutic agent(s) included in the medical device is released locally into the adjacent or surrounding tissue in a controlled manner. This controlled release may involve an initial burst release of the therapeutic agent followed by a gradient or steady-state release of lesser amounts of therapeutic agent for an extended period of time, such as at least about one month. Desirably, the therapeutic agent is released over a period of at least about one to six months. More desirably, the therapeutic agent is released over a period of at least six months. To control the rate of release of a therapeutic agent from a medical device, a variety of coating configurations may be used.

**[0052]** In one example, the medical device includes a coating comprising at least one therapeutic agent and zein/levulinic acid. In another example, the medical device comprises a coating having two or more layers, each layer preferably being distinct layers having different chemical compositions, with one layer comprising at least one therapeutic agent and a second layer comprising zein/levulinic acid. Desirably, one layer consists essentially of a (or the at least one) therapeutic agent and a second layer consists essentially of zein/levulinic acid. In one example, the coating includes a layer comprising one or more therapeutic agent(s) that is substantially free of zein/levulinic acid and a second layer comprising zein/levulinic acid and being substantially free of the therapeutic agent. The coating includes at least one layer, and preferably two or more layers. For example, in one example, a layer of therapeutic agent is deposited on at least a portion of the surface of the medical device, or on a primer layer which is placed directly on the surface of the medical device, and a layer of zein/levulinic acid is deposited on at least a portion of the therapeutic agent layer. The zein/levulinic acid layer may serve as a barrier that slows the rate of release of the therapeutic agent by providing an additional layer through which the therapeutic agent must diffuse or by providing an additional layer that must degrade before releasing the therapeutic agent beneath it.

**[0053]** In another example, at least a portion of the abluminal surface of the medical device has a layer of admixed therapeutic agent, zein and levulinic acid. The zein/levulinic acid may function to increase the biocompatibility of the medical device, and the presence of a therapeutic agent on the abluminal surface of the device allows the release of the agent directly to the location in need of therapy.

**[0054]** The present disclosure also contemplates medical devices having various multiple layer coating configurations. For example, the device may be coated with alternating layers of therapeutic agent and zein/levulinic acid, alternating layers of therapeutic agent and a mixture of therapeutic agent and zein/levulinic acid, alternating layers of zein/levulinic acid and a mixture of

therapeutic agent and zein/levulinic acid, or any other combination.

Additionally, the coating configuration may contain multiple therapeutic agents (hydrophilic and/or hydrophobic), non-polymers (such as a vitamin), a porous biostable polymer, a bioabsorbable polymer, or any combination thereof.

5 **[0055]** The thickness of the coating affects the rate of release of the therapeutic agent from the medical device. For example, in a medical device having two layers, a base layer comprising therapeutic agent and an outer layer comprising zein/levulinic acid, increasing the thickness of the zein/levulinic acid layer(s) generally slows the rate of release of the  
10 therapeutic agent(s) from the therapeutic agent layer(s). If the thickness of the coating is too large, however, the durability of the coating may be decreased. Thick layers are subject to cracking, causing a spike in therapeutic agent elution. Desirably, the thickness of each therapeutic agent layer is between about 0.1  $\mu\text{m}$  and about 10.0  $\mu\text{m}$ . The thickness of each  
15 zein/levulinic acid layer is preferably between about 1.0 and 20.0 times thicker than an adjacent layer of therapeutic agent, between about 0.1  $\mu\text{m}$  and about 200  $\mu\text{m}$ ; more preferably about 1.0 to about 5.0 times greater; and most preferably about 1.0 to about 3.0 times greater than the thickness of the therapeutic agent layer(s). More desirably, the thickness of each therapeutic  
20 agent layer is between about 0.5  $\mu\text{m}$  and about 1.0  $\mu\text{m}$  and the thickness of each layer of zein/levulinic acid is between about 1.0  $\mu\text{m}$  and about 10.0  $\mu\text{m}$ .

**[0056]** Desirably, the thickness of the entire coating (which may include one or more layers of therapeutic agent or one or more layers of zein/levulinic acid, one or more mixed layers containing both agent, zein, and levulinic acid)  
25 on the medical device is between about 0.2  $\mu\text{m}$  and about 210  $\mu\text{m}$ . The layers of therapeutic agent, the layers of zein/levulinic acid, and the mixed layers may be arranged in any configuration. More desirably, the thickness of the entire coating is between about 0.6  $\mu\text{m}$  and about 15  $\mu\text{m}$ . Even more desirably, the thickness of the entire coating is between about 0.6  $\mu\text{m}$  and  
30 about 10  $\mu\text{m}$ . For example, for a stent having six layers (three layers of therapeutic agent and three layers of zein/levulinic acid, alternating), the total

thickness of the coating layers would desirably be between about 1.5  $\mu\text{m}$  to about 66.0  $\mu\text{m}$ . Each of the layers can have the same or different thicknesses.

**[0057]** **Figure 1** shows a cross-sectional view of the surface of a coated medical device comprising a first layer of paclitaxel therapeutic agent **20** deposited on an implantable frame **10**, and a second layer of zein/levulinic acid **30** positioned over the first layer.

**[0058]** **Figure 2** shows a cross-sectional view of the surface of a second coated medical device comprising six layers deposited on an implantable frame **100**, where the first layer **120** contains zein/levulinic acid; the second layer **110** contains a therapeutic agent (desirably, paclitaxel); the third layer **122** contains zein/levulinic acid; the fourth layer **112** contains a therapeutic agent (desirably, paclitaxel); the fifth layer **124** contains zein/levulinic acid; and the sixth layer **114** contains a therapeutic agent (desirably, paclitaxel). In this example, the sixth layer **114** provides an initial "burst" of therapeutic agent, and then the zein/levulinic acid layers temporarily block the release or decrease the rate of release of the remaining layers of therapeutic agent.

**[0059]** The coating layer(s) may be deposited on the medical device in any suitable manner. For example, the coating may be deposited onto the medical device by spraying, dipping, pouring, pumping, brushing, wiping, ultrasonic deposition, vacuum deposition, vapor deposition, plasma deposition, electrostatic deposition, epitaxial growth, or any other method known to those skilled in the art.

**[0060]** **Figures 3A – 3D** show SEM images of a Zilver® stent coated with a paclitaxel base layer and a zein/levulinic acid top layer, according to the coating configuration of **Figure 1**. The SEM images of the Zilver® stent coated with paclitaxel and zein/levulinic acid are taken at magnification levels of 400x (**Figure 3A**), 140x (**Figure 3B**), 500x (**Figure 3C**), and 400x (**Figure 3D**). **Figure 4** is an SEM image of a paclitaxel-zein coated Zilver® stent. The zein layer of the stent is not admixed with levulinic acid. The zein coating is

cracked and delaminating **400, 401** from the stent as a result of the dry and brittle nature of zein before it is modified with levulinic acid. This affects the elution rate of the therapeutic agent in a less controllable fashion.

Conversely, the paclitaxel-zein/levulinic acid coated stent of **Figures 3A – 3D**  
5 do not exhibit any dry, brittle regions or delamination. The levulinic acid has added significant elasticity to the coating so that it can accommodate deformations, for example deformations related to crimping and loading.

**[0061]** The stent of **Figures 3A – 3D** was mounted on a mandrel assembly positioned in the lumen of the stent, thereby masking the lumen of  
10 the stent and preventing the lumen from being coated. Preferably, the therapeutic agent is applied by spraying a solution of a volatile solvent and about 0.5 to about 5.0 mM concentration of the therapeutic agent. For a paclitaxel therapeutic agent, a 0.6 – 4.0 mM solution (more preferably, about 0.6 – 3.0 mM) of paclitaxel in ethanol is preferably sprayed onto the abluminal  
15 surface of the stent. In the coatings shown in **Figures 3A – 3D**, the abluminal surface and interconnecting surfaces of the stent were coated with a 2.4 mM ethanolic paclitaxel solution using a pressure spray gun and a 2 g/L zein/levulinic acid methanolic solution was applied to the paclitaxel using an ultrasonic nozzle. The loaded stent was subsequently crimped to 5.5 french  
20 and sterilized with ethylene oxide.

**[0062]** In other examples, each coating layer may also be separately applied using an ultrasonic nozzle spray coating technique employing ultrasound to atomize the spray solution. A solution of about 1-5 g/L of zein in a suitable solvent such as methanol admixed with about 1-3 drops of levulinic  
25 acid per 10 mL methanolic zein solution can be applied using an ultrasonic nozzle. Ultrasonic nozzles can be configured such that excitation of the piezoelectric crystals creates a transverse standing wave along the length of the nozzle. The ultrasonic energy originating from the crystals located in the large diameter of the nozzle body undergoes a step transition and  
30 amplification as the standing wave as it traverses the length of the nozzle. The ultrasonic nozzle can be designed so that a nodal plane is located

between the crystals. For ultrasonic energy to be effective for atomization, the atomizing surface (nozzle tip) is preferably located at an anti-node, where the vibration amplitude is greatest. To accomplish this, the nozzle's length is preferably a multiple of a half-wavelength. Since wavelength is dependent upon operating frequency, nozzle dimensions can be related to operational frequency. In general, high frequency nozzles are smaller, create smaller drops, and consequently have smaller maximum flow capacity than nozzles that operate at lower frequencies. The ultrasonic nozzle can be operated at any suitable frequency, including 24 kHz, 35 kHz, 48 kHz, 60 kHz, 120 kHz or higher. Preferably, a frequency of 60 - 120 kHz or higher is used to atomize the solution of the bioabsorbable elastomer to the greatest possible extent so as to promote the formation of a smooth, uniform coating. Power can be controlled by adjusting the output level on the power supply. The nozzle power can be set at any suitable level, but is preferably about 0.9 – 1.2 W and more preferably about 1.0-1.1 W. The nozzle body can be fabricated from any suitable material, including titanium because of its good acoustical properties, high tensile strength, and excellent corrosion resistance. Liquid introduced onto the atomizing surface through a large, non-clogging feed tube running the length of the nozzle absorbs some of the vibrational energy, setting up wave motion in the liquid on the surface. For the liquid to atomize, the vibrational amplitude of the atomizing surface can be maintained within a band of input power to produce the nozzle's characteristic fine, low velocity mist. Since the atomization mechanism relies only on liquid being introduced onto the atomizing surface, the rate at which liquid is atomized depends largely on the rate at which it is delivered to the surface. Therefore, an ultrasonic nozzle can have a wide flow rate range. The maximum flow rate and median drop diameter corresponding to particular nozzle designs can be selected as design parameters by one skilled in the art. Preferably, the flow rate is between about 0.01 – 2.00 mL/min, more preferably between about 0.05-1.00 and most preferably between about 0.05-0.10 mL/min. The ultrasonic nozzle is preferably rastered over the surface of the stent with a

translational coating velocity of about 0.01 – 0.5 inches/ second, more preferably about 0.02 – 0.1 in/sec and most preferably about 0.02 – 0.08 inches/sec. The stent is preferably rotated during the coating process, for example at about 30 – 150 rpm, more preferably at about 40 – 110 rpm and  
 5 most preferably at about 90-110 rpm. The spray may be ejected from the nozzle using a suitable process gas, such as nitrogen, at a pressure that provides a desired rate of coating. The process gas is preferably nitrogen at about 0.1 – 2.5 psi, more preferably about 0.4 – 1.5 psi and most preferably about 0.5 – 1.0 psi. Preferred coating parameters for USD using a Sono-tek  
 10 Model 8700-60 ultrasonic nozzle are provided in Table 1 below:

**Table 1** Ultrasonic Spray Deposition Parameters for Sono-tek Model 8700-60

Flow rate (mL/min)	Coating velocity (in/sec)	Rotation Speed (rpm)	Nozzle Power (watts)	Process Gas (psi)	Distance (mm)
0.01-2	0.01-0.5	30-150	0.9-1.2	0.1-2.5	1 - 25

15 **[0063]** Optionally, the medical device may include a layer(s) in which the therapeutic agent is contained within the medical device itself. The medical device may have holes, wells, slots, grooves, or the like for containing the therapeutic agent or zein/levulinic acid (see, e.g., co-pending U.S. application Serial No. 10/870,079, incorporated herein by reference).  
 20 Alternatively, the therapeutic agent and/or zein/levulinic acid may be incorporated into a biodegradable structural material that releases the agent before or as the device degrades, or the therapeutic agent and/or zein/levulinic acid may be incorporated into or placed on the medical device in any other known manner. A medical device containing a therapeutic agent  
 25 within the device itself may also have deposited on the device therapeutic layer, a zein/levulinic acid layer, a layer containing both therapeutic agent and zein/levulinic acid, or any combination of the foregoing.

**[0064]** The zein/levulinic acid is preferably applied to the medical device as a solution in a suitable solvent. The zein/levulinic acid solution preferably contains zein/levulinic acid and methanol, without ethanol or a therapeutic agent. The zein/levulinic acid solution is preferably sprayed  
5 onto the surface of a medical device, or onto the surface of a therapeutic agent coating on the medical device, in a manner permitting the solvent to evaporate to leave the zein/levulinic acid adhered to the surface of the medical device. Most preferably, the zein/levulinic acid solution is sprayed from an ultrasonic nozzle onto a medical device, or onto a therapeutic  
10 agent coated on a medical device.

**[0065]** In one example, a method of coating an implantable medical device to form a drug delivery system is provided. The method may include one or more of the following steps:

**[0066]** (a) providing an implantable medical device having a surface;

15 **[0067]** (b) depositing a first layer consisting essentially of a therapeutic agent on the surface of the medical device by the steps of: applying to the surface a first solution comprising a first solvent and the therapeutic agent dispersed in the first solvent (preferably, the first solution does not contain a polymer); evaporating the first solvent to form the first coating layer consisting  
20 essentially of the therapeutic agent on the surface; repeating the application and evaporation steps until the first layer contains between about 0.05 and 2.00  $\mu\text{g}$  (preferably, 0.05 and 1.00  $\mu\text{g}$ ) of the therapeutic agent per  $\text{mm}^2$  of the coated surface; and

**[0068]** (c) depositing a second layer comprising zein/levulinic acid over  
25 the first coating layer on the medical device to form a coated medical device by the steps of: applying to the first layer a second solution comprising a second solvent and zein/levulinic acid dispersed in the second solvent;

**[0069]** (d) evaporating the second solvent to form at least a portion of the second coating layer; and

30 **[0070]** (e) repeating the application and evaporation steps until the weight or thickness of the zein/levulinic acid in the second layer is between 1

and 20 times greater than the weight or thickness of the therapeutic agent in the first layer.

**[0071]** In one aspect, the coating includes a first layer consisting essentially of, or characterized by, a desired amount of the therapeutic agent, the first layer being substantially free of zein/levulinic acid. The first layer is desirably formed by spraying a first solution of the therapeutic agent in a volatile solvent onto the surface of a medical device. The first solution is preferably formed by dissolving a taxane therapeutic agent in ethanol. The coating preferably further includes a second layer consisting essentially of, or characterized by, a desired amount of zein/levulinic acid, the second layer being substantially free of the therapeutic agent in the first layer. The first layer is preferably positioned between the second layer and a surface of the medical device. The second layer may include, or consist essentially of, zein/levulinic acid that has not been contacted with a proteolytic enzyme such as pepsin. The second layer is desirably formed by spraying a second solution of the zein/levulinic acid in a volatile solvent onto the surface of a medical device, or onto the therapeutic agent coated by spraying the first solution onto the medical device. The second solution is preferably formed by dissolving zein/levulinic acid in methanol, and preferably does not include the therapeutic agent in the first solution. More preferably, the first solution consists of paclitaxel and ethanol and the second solution consists of zein/levulinic acid and methanol. Other examples provide coatings comprising three or more layers that include a layer comprising zein and a layer comprising a therapeutic agent. Preferably, multi-layer coatings are formed by spray coating two or more solutions onto the medical device, or onto previous coating layers on the medical device. The solutions may include one or more solvents that may be the same or different from one another. Preferably, the solutions include at least one volatile solvent that evaporates under the spraying conditions, and either zein or one or more therapeutic agents.

Therapeutic Agents

**[0072]** Desirably, an implantable medical device comprises a therapeutically effective amount of one or more therapeutic agents in pure form or in derivative form. Preferably, the derivative form is a  
 5 pharmaceutically acceptable salt, ester or prodrug form. Alternatively, a medical device may be implanted in combination with the administration of a therapeutic agent from a catheter positioned within the body near the medical device, before, during or after implantation of the device.

**[0073]** Alternatively, a medical device may be implanted in combination  
 10 with the administration of a therapeutic agent from a catheter positioned within the body near the medical device, before, during or after implantation of the device.

**[0074]** Therapeutic agents that may be used in the present disclosure include, but are not limited to, pharmaceutically acceptable compositions  
 15 containing any of the therapeutic agents or classes of therapeutic agents listed herein, as well as any salts and/or pharmaceutically acceptable formulations thereof. Table 2 below provides a non-exclusive list of classes of therapeutic agents and some corresponding exemplary active ingredients.

**Table 2**

<b>Therapeutic Agent Class</b>	<b>Exemplary Therapeutic Agent Active Ingredients</b>
Adrenergic agonist	Adrafinil Isometheptene Ephedrine (all forms)
Adrenergic antagonist	Monatepil maleate Naftopidil Carvedilol Moxisylyte HCl
Adrenergic - Vasoconstrictor/Nasal decongestant	Oxymetazoline HCl Norfenefrine HCl Bretylum Tosylate
Adrenocorticotrophic hormone	Corticotropin

Therapeutic Agent Class	Exemplary Therapeutic Agent Active Ingredients
Analgesic	Bezitramide Bupivacaine Acetylsalicylic acid Propanidid Lidocaine Pseudophedrine HCl Acetaminophen Chlorpheniramine Maleate
Anesthetics	Dyclonine HCl Hydroxydione Sodium Acetamidoeugenol
Anthelmintics	Niclosamide Thymyl N-Isoamylcarbamate Oxamniquine Nitroxynil N-ethylglucamine Anthiolimine 8-Hydroxyquinoline Sulfate
Anti-inflammatory	Bendazac Bufexamac Desoximetasone Amiprilose HCl Balsalazide Disodium Salt Benzydamine HCl
Antiallergic	Fluticasone propionate Pemirolast Potassium salt Cromolyn Disodium salt Nedocromil Disodium salt
Antiamebic	Cephaeline Phanquinone Thiocarbarosone

Therapeutic Agent Class	Exemplary Therapeutic Agent Active Ingredients
Antianemic	Folarin Calcium folinate
Antianginal	Verapamil Molsidomine Isosorbide Dinitrate Acebutolol HCl Bufetolol HCl Timolol Hydrogen maleate salt
Antiarrythmics	Quinidine Lidocaine Capobenic Acid Encainide HCl Bretylium Tosylate Butobendine Dichloride
Antiarthritics	Azathioprine Calcium 3-aurothio-2-propanol-1-sulfate Glucosamine Beta Form Actarit
Antiasthmatics/Leukotriene antagonist	Cromalyn Disodium Halamid Montelukast Monosodium salt
Antibacterial	Cefoxitin Sodium salt Lincolcina Colisititn sulfate
Antibiotics	Gentamicin Erythromycin Azithromycin
Anticoagulants	Heparin sodium salt Dextran Sulfate Sodium

Therapeutic Agent Class	Exemplary Therapeutic Agent Active Ingredients
Anticonvulsants	Paramethadione Phenobarbital sodium salt Levetiracetam
Antidepressants	Fluoxetine HCl Paroxetine Nortriptyline HCl
Antidiabetic	Acarbose Novorapid Diabex
Antiemetics	Chlorpromazine HCl Cyclizine HCl Dimenhydrinate
Antiglaucoma agents	Dorzolamide HCl Epinephrine (all forms) Dipivefrin HCl
Antihistamines	Histapyrrodine HCl
Antihyperlipoproteinemic	Lovastatin Pantethine
Antihypertensives	Atenolol Guanabenz Monoacetate Hydroflumethiazide
Antihyperthyroid	Propylthiouracil Iodine
Antihypotensive	Cortensor Pholedrine Sulfate Norepinephrine HCl
Antimalarials	Cinchonidine Cinchonine Pyrimethamine

Therapeutic Agent Class	Exemplary Therapeutic Agent Active Ingredients
	Amodiaquin 2 HCl dihydrate Bebeerine HCl Chloroquine Diphosphate
Antimigraine agents	Dihydroergotamine Ergotamine Eletriptan Hydrobromide Valproic Acid Sodium salt Dihydroergotamine mesylate
Antineoplastic	9-Aminocamptothecin Carboquone Benzodepa Bleomycins Capecitabine Doxorubicin HCl
Antiparkinsons agents	Methixene Terguride Amantadine HCl Ethylbenzhydramine HCl Scopolamine <i>N</i> -Oxide Hydrobromide
Antiperistaltic; antidiarrheal	Bismuth Subcarbonate Bismuth Subsalyclate Mebiquine Diphenoxylate HCl
Antiprotozoal	Fumagillin Melarsoprol Nitazoxanide Aeropent Pentamideine Isethionate Oxophenarsine HCl
Antipsycotics	Chlorprothixene

Therapeutic Agent Class	Exemplary Therapeutic Agent Active Ingredients
	Cyamemazine Thioridazine Haloperidol HCl Triflupromazine HCl Trifluoperidol HCl
Antipyretics	Dipyrocetyl Naproxen Tetrandrine Imidazole Salicylate Lysine Acetylsalicylate Magnesium Acetylsalicylate
Antirheumatic	Auranofin Azathioprine Myoral Penicillamine HCl Chloroquine Diphosphate Hydroxychloroquine Sulfate
Antispasmodic	Ethaverine Octaverine Rociverine Ethaverine HCl Fenpiverinium Bromide Leiopyrrole HCl
Antithrombotic	Plafibrade Triflusal Sulfinpyrazone Ticlopidine HCl
Antitussives	Anethole Hydrocodone Oxeladin

Therapeutic Agent Class	Exemplary Therapeutic Agent Active Ingredients
	Amicibone HCl Butethamate Citrate Carbetapentane Citrate
Antiulcer agents	Polaprezinc Lafutidine Plaunotol Ranitidine HCl Pirenzepine 2 HCl Misoprostol
Antiviral agents	Nelfinavir Atazanavir Amantadine Acyclovir Rimantadine HCl Epivar Crixivan
Anxiolytics	Alprazolam Cloxazolam Oxazolam Flesinoxan HCl Chlordiazepoxide HCl Clorazepic Acid Dipotassium salt
Bronchodialtor	Epinephrine Theobromine Dypylline Eprozinol 2HCl Etafedrine
Cardiotonics	Cymarin Oleandrin Docarpamine

Therapeutic Agent Class	Exemplary Therapeutic Agent Active Ingredients
	Digitalin Dopamine HCl Heptaminol HCl
Cholinergic	Eseridine Physostigmine Methacholine Chloride Edrophonium chloride Juvastigmin
Cholinergic antagonist	Pehencarbamide HCl Glycopyrrolate Hyoscyamine Sulfate dihydrate
Cognition enhancers/Nootropic	Idebenone Tacrine HCl Aceglutamide Aluminum Complex Acetylcarnitine L HCl
Decongestants	Propylhexedrine <i>d</i> -Form Pseudoephedrine Tuaminoheptane Cyclopentamine HCl Fenoxazoline HCl Naphazoline HCl
Diagnostic aid	Disofenin Ethiodized Oil Fluorescein Diatrizoate sodium Meglumine Diatrizoate
Diuretics	Bendroflumethiazide Fenquizone Mercurous Chloride Amiloride HCl 2•H <sub>2</sub> O

Therapeutic Agent Class	Exemplary Therapeutic Agent Active Ingredients
	Manicol Urea
Enzyme inhibitor (proteinase)	Gabexate Methanesulfonate
Fungicides	Candididin Filipin Lucensomycin Amphotericin B Caspofungin Acetate Viridin
Gonad stimulating principle	Clomiphene Citrate Chorionic gonadotropin Humegon Luteinizing hormone (LH)
Hemorrhologic agent	Poloxamer 331 Azupentat
Hemostatic	Hydrastine Alginic Acid Batroxobin 6-Aminohexanoic acid Factor IX Carbazochrome Salicylate
Hypolipemic agents	Clofibrilic Acid Magnesium salt Dextran Sulfate Sodium Meglutol
Immunosuppresants	Azathioprine 6-Mercaptopurine Prograf Brequinar Sodium salt Gusperimus 3 HCl Mizoribine


Therapeutic Agent Class	Exemplary Therapeutic Agent Active Ingredients
	Rapamycin and analogs thereof
Mydriatic; antispasmodic	Epinephrine Yohimbine Aminopentamide <i>dl</i> -Form Atropine Methylnitrate Atropine Sulfatemonohydrate Hydroxyamphetamine (l, HCl, HBr)
Neuromuscular blocking agent/ Muscle relaxants (skeletal)	Phenprobamate Chlorzoxazone Mephenoxalone Mioblock Doxacurium Chloride Pancuronium bromide
Oxotocic	Ergonovine Tartrate hydrate Methylergonovine Prostaglandin F <sub>2α</sub> Intertocine-S Ergonovine Maleate Prostaglandin F <sub>2α</sub> Tromethamine salt
Radioprotective agent	Amifostine 3H <sub>2</sub> O
Sedative/Hypnotic	Haloxazolam Butalbital Butethal Pentaerythritol Chloral Diethylbromoacetamide Barbital Sodium salt
Serenic	Eltoprazine
Tocolytic agents	Albuterol Sulfate Terbutaline sulfate

Therapeutic Agent Class	Exemplary Therapeutic Agent Active Ingredients
Treatment of cystic fibrosis	Uridine 5'-Triphosphate Trisodium dihydrate salt
Vasoconstrictor	Nordefrin (-) Form Propylhexedrine <i>dl</i> -form Nordefrin HCl
Vasodilators	Nylidrin HCl Papaverine Erythrityl Tetranitrate Pentoxifylline Diazenium diolates Citicoline Hexestrol Bis(diethylaminoethyl ether) 2HCl
Vitamins	$\alpha$ -Carotene $\beta$ -Carotene Vitamin D <sub>3</sub> Pantothenic Acid sodium salt

**[0075]** Other desirable therapeutic agents include, but are not limited to, the following: (a) anti-inflammatory/immunomodulators such as dexamethasone, m-prednisolone, interferon g-1b, leflunomide, sirolimus, tacrolimus, everolimus, pimecrolimus, biolimus (such as Biolimus A7 or A9) mycophenolic acid, mizoribine, cyclosporine, tranilast, and viral proteins; (b) antiproliferatives such as paclitaxel or other taxane derivatives (such as QP-2), actinomycin, methothrexate, angiopeptin, vincristine, mitomycine, statins, C MYC antisense, ABT-578, RestenASE, Resten-NG, 2-chloro-deoxyadenosine, and PCNA ribozyme; (c) migration inhibitors/ECM-modulators such as batimastat, prolyl hydroxylase inhibitors, halofuginone, C proteinase inhibitors, and probucol; and (d) agents that promote healing and re-endothelialization such as BCP671, VEGF, estradiols (such as 17-beta

estradiol (estrogen)), NO donors, EPC antibodies, bioest, ECs, CD-34 antibodies, and advanced coatings.

**[0076]** A preferred class of therapeutic agents which may be employed in the present disclosure are the family of so-called taxanes. These  
 5 comprise molecules containing the core fused ring chemical structure shaded in structure (1) below, with four fused rings ("core taxane structure," shaded in structure (1)), with several substituents.




(1)

**[0077]** In another embodiment, the therapeutic agent can be a taxane analog or derivative characterized by variation of the paclitaxel structure (1). Taxanes in general, and paclitaxel is particular, is considered to function as a cell cycle inhibitor by acting as an anti- microtubule agent, and more specifically as a stabilizer. Preferred taxane analogs and derivatives  
 15 core vary the substituents attached to the core taxane structure.

**[0078]** Within some preferred embodiments of the disclosure, the therapeutic agent is a taxane cell cycle inhibitor, such as paclitaxel, a paclitaxel analogue or paclitaxel derivative compound. Paclitaxel is a bioactive compound which disrupts mitosis (M-phase) by binding to tubulin to  
 20 form abnormal mitotic spindles or an analogue or derivative thereof. Briefly, paclitaxel is a highly derivatized diterpenoid (Wani et al., *J. Am. Chem. Soc.* 93: 2325, 1971) which has been obtained from the harvested and dried bark

of *Taxus brevifolia* (Pacific Yew) and *Taxomyces Andreanae* and Endophytic Fungus of the Pacific Yew (Stierle et al., *Science* 60: 214-216, 1993).

**[0079]** In one embodiment, the therapeutic agent is a taxane analog or derivative including the core taxane structure (1) and the methyl 3-(benzamido)-2-hydroxy-3-phenylpropanoate moiety (shown in structure (2) below) at the 13-carbon position ("C13") of the core taxane structure (outlined with a dashed line in structure (1)).



(2)

**[0080]** It is believed that structure (2) at the 13-carbon position of the core taxane structure plays a role in the biological activity of the molecule as a cell cycle inhibitor. Examples of therapeutic agents having structure (2) include paclitaxel (Merck Index entry 7117), docetaxol (TAXOTERE, Merck Index entry 3458), and 3'-desphenyl-3'-(4-ntiropenyl)-N- dibenzoyl-N-(t-butoxycarbonyl)-10-deacetyltaxol.

**[0081]** A therapeutic agent composition comprising a taxane compound can include formulations, prodrugs, analogues and derivatives of paclitaxel such as, for example, TAXOL (Bristol Myers Squibb, New York, N.Y.), TAXOTERE (Aventis Pharmaceuticals, France), docetaxel, 10-desacetyl analogues of paclitaxel and 3'-N-desbenzoyl-3'-N-t-butoxy carbonyl analogues of paclitaxel. Paclitaxel has a molecular weight of about 853 amu, and may be readily prepared utilizing techniques known to those skilled in the art (see, e.g., Schiff et al., *Nature* 277: 665-667, 1979; Long and Fairchild, *Cancer Research* 54: 4355-4361, 1994; Ringel and Horwitz, *J. Nat'l Cancer Inst.* 83 (4): 288-291, 1991; Pazdur et al., *Cancer Treat. Rev.* 19 (4): 351-386, 1993; *Tetrahedron Letters* 35 (52): 9709-9712, 1994; *J. Med. Chem.* 35: 4230-4237, 1992; *J. Med. Chem.* 34: 992-998, 1991; *J. Natural Prod.* 57 (10):

1404-1410, 1994; *J. Natural Prod.* 57 (11): 1580-1583, 1994; *J. Am. Chem. Soc.* 110: 6558-6560, 1988), or obtained from a variety of commercial sources, including for example, Sigma Chemical Co., St. Louis, Mo. (T7402-- from *Taxus brevifolia*).

5 **[0082]** Any single therapeutic agent or combination of therapeutic agents may be used in the medical device. Desirably, the therapeutic agent is paclitaxel or a derivative thereof. Paclitaxel may be used to prevent restenosis by preventing chronic inflammation (by preventing the division of affected cells by stabilizing the microtubule function) and by preventing cell  
10 migration (by preventing the cell with destructive potential from migrating and accumulating at the injured site).

#### Dose Levels of Therapeutic Agents

**[0083]** The therapeutically effective amount of therapeutic agent that is  
15 provided in connection with the various embodiments ultimately depends upon the condition and severity of the condition to be treated; the type and activity of the specific therapeutic agent employed; the method by which the medical device is administered to the patient; the age, body weight, general health, gender and diet of the patient; the time of administration, route of  
20 administration, and rate of excretion of the specific compound employed; the duration of the treatment; drugs used in combination or coincidental with the specific compound employed; and like factors well known in the medical arts.

**[0084]** Local administration of therapeutic agents may be more effective when carried out over an extended period of time, such as a time  
25 period at least matching the normal reaction time of the body to an angioplasty procedure. At the same time, it may be desirable to provide an initial high dose of the therapeutic agent over a preliminary period. For example, local administration of a therapeutic agent over a period of days or even months may be most effective in treating or inhibiting conditions such as  
30 restenosis.

**[0085]** For the purposes of local delivery from a stent, the daily dose that a patient will receive depends at least on the length of the stent. For example, a 15 mm long cylindrical radially expandable stent may contain a therapeutic agent in an amount ranging from about 1  $\mu\text{g}$  to about 120  $\mu\text{g}$  and  
5 may deliver that therapeutic agent over a time period ranging from several hours to several months, preferably up to about 1 to 6 months. Optionally, the medical device may be a stent adapted for placement in a peripheral, rather than coronary, artery (for instance, to treat peripheral vascular disease). To obtain the desired dosage of therapeutic agent, the thickness of  
10 the layer(s) may be varied, as well as the ratio of the zein/levulinic acid to the therapeutic agent. Preferably, the ratio of the weight of zein/levulinic acid to the therapeutic agent is about 1:1 to 20:1, more preferably about 5:1 to about 20:1, about 10:1 to about 20:1, about 15:1 to about 20:1 and most preferably about 17:1 to about 20:1, including ratios of 20, 19, 18, 17, 16, 15, 14, 13, 12,  
15 11, 10, 9, 8, 7, 6, 5, 4, 3, 2 and 1 part zein/levulinic acid to 1 part of the therapeutic agent.

#### Therapeutic Agent Elution Profile

**[0086]** The therapeutic agent elution profile of a medical device  
20 comprising a therapeutic agent can be obtained by any suitable method that allows for measurement of the release of the therapeutic agent with a desired level of accuracy and precision. For purposes of this application, unless otherwise specified, the elution profile of the release of a therapeutic agent was obtained by contacting the medical device with a test solvent, such as a  
25 porcine serum or an aqueous cyclodextrin solution. A suitable test solvent solubilizes a therapeutic agent while allowing for subsequent measurement of the solubilized therapeutic agent in a manner that can be correlated to the amount of therapeutic agent released from the medical device. For example, porcine serum can be used to simulate implantation within a blood vessel.

30 **[0087]** The release of therapeutic agent from the medical device can be subsequently measured by any suitable spectrographic method, such as

measurement of a UV absorption spectrum of an aqueous test solvent after contacting the medical device, or by use of an HPLC spectrophotometer with a UV-VIS detector, or a Liquid Chromatography paired with a Mass spec detector. A suitable method, such as a spectrographic technique, permits  
5 measurement of a property of the test solution that can be correlated to the presence or concentration of the therapeutic agent analyte with a desired level of accuracy and precision.

**[0088]** **Figure 5** shows a graph of a drug elution from a paclitaxel coated stent, without a zein/levulinic layer, in porcine serum. The elution  
10 graph shows the percent of 961 µg of paclitaxel eluted from a paclitaxel-coated 6x80 mm Zilver® stent in porcine serum as a function of time. The elution rate profile of the drug shows a high rate of drug delivery over an initial period of about 2 hours or so after stent contact with the porcine serum, with minimal drug eluted over the next several hours.

**[0089]** Elution profiles of stents coated with a layer of paclitaxel and a layer of zein/levulinic acid are shown in the examples below. Desirably, the medical device is configured to provide elution of therapeutic agent over at least about 3 to 6 months following introduction of the device into a physiological environment.

**[0090]** Coating zein/levulinic over the paclitaxel-coated stent described with reference to **Figure 5** results in a notable change in the drug elution profile of paclitaxel. **Figure 6** shows a graph of drug elution in HCD from a sterilized paclitaxel-zein/levulinic coated stent, in accordance with one  
20 embodiment of the present disclosure. The elution graph shows the elution of paclitaxel from a sterilized paclitaxel-zein/levulinic coated stent in HCD.  
25 Elution media comprising HCD allows for rapid dissolution compared to porcine serum, used in **Figure 5**. HCD was selected to provide desirably rapid therapeutic agent elution rates that remain dependent upon and indicative of the stent coating composition.

**[0091]** The stent is coated on the abluminal surface, with a first layer of paclitaxel and a second layer of zein positioned over the first layer. The  
30

elution of therapeutic agent is indicated as a percentage by weight of total drug initially deposited on the stent. Typical units for drug elution include micrograms of drug. The **Figure 6** zein/levulinic acid-coated stent elution rate profile shows a substantially slower *in vivo* rate of drug elution compared to  
5 the paclitaxel-only stent elution profile of **Figure 5**, and was obtained from a stent coated only on the abluminal surface with 21 µg of paclitaxel in a first layer covered with 105 µg of zein/levulinic acid in a second layer. The zein/levulinic acid layer comprises 1 drop of levulinic per 10 mL of Methanolic zein solution (about 4 g/L).

10 **[0092]** **Figure 7** shows the percent of paclitaxel eluted over 4 hours in 5% HCD as a function of the ratio of paclitaxel to zein/levulinic acid. The correlation between the percent of paclitaxel eluted and the paclitaxel-zein/levulinic acid ration is a simple linear equation, illustrating that the elution of a therapeutic agent can be easily controlled by varying the amount of  
15 zein/levulinic acid. An increase in the ratio of zein/levulinic acid to paclitaxel yields a slower elution rate. A decrease in the ratio of zein/levulinic acid to paclitaxel generates a faster controlled elution rate.

#### Medical Devices

20 **[0093]** The present disclosure is applicable to implantable or insertable medical devices of any shape or configuration. Typical subjects (also referred to herein as "patients") are vertebrate subjects (i.e., members of the subphylum cordata), including, mammals such as cattle, sheep, pigs, goats, horses, dogs, cats and humans.

25 **[0094]** Typical sites for placement of the medical devices include the coronary and peripheral vasculature (collectively referred to herein as the vasculature), heart, esophagus, trachea, colon, gastrointestinal tract, biliary tract, urinary tract, bladder, prostate, brain and surgical sites. Where the medical device is inserted into the vasculature, for example, the therapeutic  
30 agent may be released to a blood vessel wall adjacent the device, and may also be released to downstream vascular tissue as well.

**[0095]** The medical device may be any device that is introduced temporarily or permanently into the body for the prophylaxis or therapy of a medical condition. For example, such medical devices may include, but are not limited to, stents, stent grafts, vascular grafts, catheters, guide wires, 5 balloons, filters (e.g., vena cava filters), cerebral aneurysm filler coils, intraluminal paving systems, sutures, staples, anastomosis devices, vertebral disks, bone pins, suture anchors, hemostatic barriers, clamps, screws, plates, clips, slings, vascular implants, tissue adhesives and sealants, tissue scaffolds, myocardial plugs, pacemaker leads, valves (e.g., venous valves), 10 abdominal aortic aneurysm (AAA) grafts, embolic coils, various types of dressings, bone substitutes, intraluminal devices, vascular supports, or other known bio-compatible devices.

**[0096]** In general, intraluminal stents for use in connection with the present disclosure typically comprise a plurality of apertures or open spaces 15 between metallic filaments (including fibers and wires), segments or regions. Typical structures include: an open-mesh network comprising one or more knitted, woven or braided metallic filaments; an interconnected network of articable segments; a coiled or helical structure comprising one or more metallic filaments; and, a patterned tubular metallic sheet (e.g., a laser cut 20 tube). Examples of intraluminal stents include endovascular, biliary, tracheal, gastrointestinal, urethral, esophageal and coronary vascular stents. The intraluminal stents may be, for example, balloon-expandable or self-expandable. Thus, although certain embodiments will be described herein with reference to vascular stents, the present disclosure is applicable to other 25 medical devices, including other types of stents.

**[0097]** In one embodiment, the medical device comprises an intraluminal stent. The stent may be self-expanding or balloon-expandable and may be a bifurcated stent, a stent configured for any blood vessel including coronary arteries and peripheral arteries (e.g., renal, Superficial 30 Femoral, Carotid, and the like), a urethral stent, a biliary stent, a tracheal stent, a gastrointestinal stent, or an esophageal stent, for example. More

specifically, the stent may be, for example, a Wallstent, Palmaz-Shatz, Wiktor, Strecker, Cordis, AVE Micro Stent, Igaki-Tamai, Millenium Stent (Sahajanand Medical Technologies), Steeplechaser stent (Johnson & Johnson), Cypher (Johnson & Johnson), Sonic (Johnson & Johnson), BX Velocity (Johnson & Johnson), Flexmaster (JOMED) JoStent (JOMED), S7 Driver (Medtronic), R-Stent (Orbus), Tecnic stent (Sorin Biomedica), BiodivYsio (Biocompatibles Cardiovascular), Trimaxx (Abbott), DuraFlex (Avantec Vascular), NIR stent (Boston Scientific), Express 2 stent (Boston Scientific), Liberte stent (Boston Scientific), Achieve (Cook/Guidant), S-Stent (Guidant), Vision (Guidant), Multi-Link Tetra (Guidant), Multi-Link Penta (Guidant), or Multi-Link Vision (Guidant). Some exemplary stents are also disclosed in U.S. Patent Nos. 5,292,331 to Boneau, 6,090,127 to Globerman, 5,133,732 to Wiktor, 4,739,762 to Palmaz, and 5,421,955 to Lau. Desirably, the stent is a vascular stent such as the commercially available Gianturco-Roubin FLEX-STENT®, GRII™, SUPRA-G, or V FLEX coronary stents from Cook Inc. (Bloomington, IN).

**[0098]** The stent may be formed through various methods, such as welding, laser cutting, sputter deposition, or molding, or it may consist of filaments or fibers that are wound or braided together to form a continuous structure. The stent may also be a grafted stent in which the therapeutic agent is incorporated into the graft material. The stent may be deployed according to conventional methodology, such as by an inflatable balloon catheter, by a self-deployment mechanism (after release from a catheter), or by other appropriate means.

**[0099]** The stent or other medical device may be made of one or more suitable biocompatible materials such as stainless steel, nitinol, MP35N, gold, tantalum, platinum or platinum iridium, niobium, tungsten, iconel, ceramic, nickel, titanium, stainless steel/titanium composite, cobalt, chromium, cobalt/chromium alloys, magnesium, aluminum, or other biocompatible metals and/or composites or alloys such as carbon or carbon fiber, cellulose acetate, cellulose nitrate, silicone, cross-linked polyvinyl alcohol (PVA) hydrogel,

cross-linked PVA hydrogel foam, polyurethane, polyamide, styrene isobutylene-styrene block copolymer (Kraton), polyethylene terephthalate, polyurethane, polyamide, polyester, polyorthoester, polyanhydride, polyether sulfone, polycarbonate, polypropylene, high molecular weight polyethylene, polytetrafluoroethylene, or other biocompatible polymeric material, or mixture of copolymers thereof; polyesters such as, polylactic acid, polyglycolic acid or copolymers thereof, a polyanhydride, polycaprolactone, polyhydroxybutyrate valerate or other biodegradable polymer, or mixtures or copolymers thereof; extracellular matrix components, proteins, collagen, fibrin or other therapeutic agent, or mixtures thereof. Desirably, the device is made of stainless steel or nitinol.

#### Surface Preparation

**[00100]** It may be advantageous to prepare the surface of a medical device before depositing a coating thereon. Useful methods of surface preparation may include, but are not limited to: cleaning; physical modifications such as etching, drilling, cutting, or abrasion; chemical modifications such as solvent treatment; application of primer coatings or surfactants; plasma treatment; ion bombardment; and covalent bonding. Such surface preparation may activate the surface and promote the deposition or adhesion of the coating on the surface. Surface preparation may also selectively alter the release rate of the bioactive material. Any additional coating layers may similarly be processed to promote the deposition or adhesion of another layer, to further control the release rate of the therapeutic agent, or to otherwise improve the biocompatibility of the surface of the layers. For example, plasma treating an additional coating layer before depositing a therapeutic agent thereon may improve the adhesion of the therapeutic agent, increase the amount of therapeutic agent that can be deposited, and allow the bioactive material to be deposited in a more uniform layer.

**[00101]** A primer layer, or adhesion promotion layer, may be used with the medical device. This layer may include, for example, silane, acrylate polymer/copolymer, acrylate carboxyl and/or hydroxyl copolymer, polyvinylpyrrolidone/vinylacetate copolymer, olefin acrylic acid copolymer, 5 ethylene acrylic acid copolymer, epoxy polymer, polyethylene glycol, polyethylene oxide, polyvinylpyridine copolymers, polyamide polymers/copolymers polyimide polymers/copolymers, ethylene vinylacetate copolymer and/or polyether sulfones.

#### 10 Methods of Treatment

**[00102]** A method of treatment involves inserting into a patient a coated medical device having any of the configurations described above. For example, when the medical device is a stent coated as described above, the method of treatment involves implanting the stent into the vascular system of 15 a patient and allowing the therapeutic agent(s) to be released from the stent in a controlled manner, as shown by the drug elution profile of the coated stent.

**[00103]** Although exemplary embodiments of the disclosure have been described with respect to the treatment of complications such as restenosis following an angioplasty procedure, the local delivery of therapeutic agents 20 may be used to treat a wide variety of conditions using any number of medical devices. For example, other medical devices that often fail due to tissue ingrowth or accumulation of proteinaceous material in, on, or around the device may also benefit from the present disclosure. Such devices may include, but are not limited to, intraocular lenses, shunts for hydrocephalus, 25 dialysis grafts, colostomy bag attachment devices, ear drainage tubes, leads for pace makers, and implantable defibrillators.

**[00104]** In one embodiment, a method of delivering a therapeutic agent to a body vessel, such as a peripheral blood vessel is provided. The method may include one or more of the following steps:

- 30 (a) providing a coated vascular stent comprising a radially-expandable vascular stent having an abluminal side and a luminal side defining a

substantially cylindrical lumen and being movable from a radially expanded configuration to a radially compressed configuration; and a multi-layer coating on the abluminal surface.

- 5 (b) intralumenally inserting the coated vascular stent into the blood vascular system using a means for intraluminal delivery comprising a catheter;
- (c) positioning the coated vascular stent within a peripheral artery; and
- 10 (d) radially expanding the coated vascular stent within the peripheral artery so as to place the coated vascular stent in contact with a portion of a wall of the peripheral artery in a manner effective to deliver the therapeutic agent to the wall of the peripheral artery.

**[00105]** The multi-layer may include two or more layers, but typically includes a first layer comprising a therapeutic agent and a second layer comprising zein/levulinic acid positioned over the first layer and the first layer positioned between the surface and a second layer. The first layer preferably includes between about 0.05 and 2.00  $\mu\text{g}$ , more preferably about 0.05 to 1.00  $\mu\text{g}$  of a taxane therapeutic agent, such as paclitaxel, per  $\text{mm}^2$  of the coated surface, and less than 0.1  $\mu\text{g}$  of a polymer. The second layer preferably includes between about 0.05 and 40  $\mu\text{grams}$  of zein/levulinic acid per  $\text{mm}^2$  of the coated surface, the total amount of zein/levulinic acid preferably being present in an amount between 1 and 20 times the weight of the therapeutic agent in the first layer.

15

20

**[00106]** A consensus document has been assembled by clinical, academic, and industrial investigators engaged in preclinical interventional device evaluation to set forth standards for evaluating drug-eluting stents such as those contemplated by the present disclosure. See "Drug-Eluting Stents in Preclinical Studies – Recommended Evaluation From a Consensus Group" by Schwartz and Edelman (available at <http://www.circulationaha.org>) (incorporated herein by reference).

25

30 **[00107]** While various aspects and examples have been described, it will be apparent to those of ordinary skill in the art that many more examples and

implementations are possible within the scope of the disclosure. Accordingly, the disclosure is not to be restricted except in light of the attached claims and their equivalents.

## EXAMPLES

*Example 1: Single layer of zein/levulinic acid over single layer of paclitaxel on a stent*

**[00108]** Paclitaxel was applied to several 6x20 mm Zilver® stents (nitinol stents manufactured by Cook Inc.) as follows. First, paclitaxel was dissolved in ethanol to form a 2.4 mM solution. The paclitaxel was substantially dissolved within about 30 minutes, using sonication. The paclitaxel solution was then filtered through a 0.2 micron nylon filter and collected in a flask.

**[00109]** Approximately 10 mL +/- 0.1 mL of ethanol was filtered through a 0.2 micron nylon filter and then transferred into a reservoir connected to a pressure spray gun nozzle. This solution was then used to set the flow rate of the pressure spray gun to the target flow rate of approximately 5.7 mL/min. +/- mL/min.

**[00110]** Some stents were mounted on a mandrel assembly positioned in the lumen of the stent, including a silicon tube covering a steel rod. This assembly masked the lumens of the stents and substantially prevented the lumens from being coated.

**[00111]** Approximately 25 mL of the filtered paclitaxel solution was added to the spray gun reservoir, and the solution was sprayed onto the stents using a HEPA filtered hood and a fluid dispensing system connected to a pressure source (nitrogen) until the target dose of paclitaxel was reached (for comparison, some stents were coated with more paclitaxel than others). Adjustments on the system were used to control the spray pattern and the amount of fluid dispensed. The spray gun was aligned with the stents by setting a laser beam even with the nozzle of the spray gun and positioning the stents so that the laser beam was located at approximately one quarter ( $\frac{1}{4}$ ) the distance from the top of the stents. The spray gun, which was positioned parallel to the hood floor and at a horizontal distance of approximately 12-18 centimeters from the stents, was then passed over the surface of the stents until a predetermined volume of spray was dispensed. The stents were then

rotated approximately 90 degrees and the spraying procedure was repeated until the entire circumference of each stent was coated. The movement of the gun was slow enough to allow the solvent to evaporate before the next pass of the gun. Each spray application covered approximately 90 degrees of the circumference of the stents. The stents were kept at ambient temperature and humidity during the spraying process, and the solution was pumped at a rate of approximately 6 mL/min through the pressure spray gun. After substantially all of the solvent had evaporated, a coating of paclitaxel between about .07  $\mu\text{g mm}^{-2}$  and about 1.37  $\mu\text{g mm}^{-2}$  was left on the stent.

**[00112]** Zein was then applied over the paclitaxel coating. A solution of approximately 4 g/L of zein in methanol was prepared, filtered over a 0.2 micron nylon filter, and collected in a flask. The Methanolic solution of zein was then admixed with about 1 drop levulinic acid per 10 mLs of methanolic zein solution. The zein/levulinic acid solution was deposited over the layer of paclitaxel using an ultrasonic nozzle. The ultrasonic nozzle power was about 1.1 watts with a flow rate between .06 mL/min. and .08 mL/min. The nozzle was positioned at a horizontal distance of between approximately 11 mm and 15 mm from the stents. The zein/levulinic acid solution was coated on the stent at a velocity of about 25.5 mm/sec.

**[00113]** The coated stent was sterilized with ethylene oxide, and loaded into a flask containing HCD. Samples were taken at intervals and analyzed for paclitaxel. Numerical data for some of the resulting coated stents is shown in tables 3 and 4 below.

**Table 3**

21 $\mu\text{g}$ PTX / 21 $\mu\text{g}$ Zein/Levulinic Acid	
Time (min)	% PTX Eluted
0	0
1	1.7
3	7.1
7	12.8
15	23.5
30	44.3
45	53.6
60	58.9
120	65.2

180	67.3
240	67.9

**Table 4**

21 $\mu\text{g}$ PTX / 210 $\mu\text{g}$ Zein/Levulinic Acid	
Time (min)	% PTX Eluted
0	0
1	10.2
3	14.8
7	18.9
15	24.9
30	32.0
45	36.7

60	39.7
120	46.6
180	50.1
240	52.7

*Example 2: Ultrasonic Coating of Multi-layer Coating*

**[00114]** Several multilayer coatings were applied to several 6x20 mm Zilver® stents (Cook Inc., Bloomington, IN). All coating layers were applied from a Sono-tek Model 8700-60 ultrasonic nozzle operated at parameters within Table 1 above. First, a solution of 0.7 – 4.8 mM paclitaxel in ethanol was sprayed onto the abluminal surface of each stent using the ultrasonic nozzle operated within the parameters provided in Table 1 above. Second, after application of the paclitaxel, a second solution of zein ~4 g/L in methanol was admixed with about 1 drop levulinic acid per 10 mL methanolic zein. The zein/levulinic acid solution was sprayed over the paclitaxel using the Sono-tek Model 8700-60 ultrasonic nozzle according to the parameters in Table 1.

**[00115]** Each solution was separately loaded into a 10.0 mL syringe, which was mounted onto a syringe pump and connected to a tube that carries the solution to a spray head. The syringe pump was then used to purge the air from the solution line and prime the line and spray nozzle with the solution. The ultrasonic nozzle is arranged such that excitation of the piezoelectric crystals generates a transverse standing wave along the length of the nozzle. The solution introduced onto the atomizing surface absorbs some of the vibrational energy, setting up wave motion in the liquid. By coating the solution according to the parameters in Table 1, the vibrational amplitude of the atomizing surface was adequate to provide a desired spray for application of the paclitaxel or zein/levulinic acid. The coating chamber is purged with nitrogen to displace any oxygen in the system. After that, the stent is loaded onto a mandrel and coated. The ultrasonic nozzle was manually aligned to the tip of each end of the stent. These position numbers are used for the coating program for when the syringe pump is actually activated. During the process, the stent is kept at ambient temperature and in a closed chamber.

30

## CLAIMS

We claim:

1. A medical device comprising a frame and a coating, the coating comprising zein or modified zein admixed with levulinic acid.
2. The device of claim 1, wherein the coating further comprises therapeutic agent.
3. The device of claim 2, wherein the therapeutic agent is hydrophobic.
4. The device of claim 2, wherein the coating further comprises about 1:1 to about 1:20 weight ratio of therapeutic agent to zein or modified zein admixed with levulinic acid.
5. The device of claim 2, wherein the coating further comprises about 1:1 to about 1:5 weight ratio of therapeutic agent to zein or modified zein admixed with levulinic acid.
6. The medical device of claim 1, wherein the coating further comprises at least two layers, a first layer comprising a therapeutic agent and a second layer comprising zein or modified zein admixed with levulinic acid.
7. The medical device of claim 6, wherein the second layer at least partially covers the first layer.
8. The device of claim 6, wherein the first layer is substantially covered by the second layer.
9. The device of claim 2, wherein the therapeutic agent is selected from the group consisting of anti-inflammatory/immunomodulators, antiproliferatives, migration inhibitors/ECM-modulators, and agents that promote healing.

10. The device of claim 9, wherein the therapeutic agent is paclitaxel or a paclitaxel derivative.
11. The device of claim 1, wherein the thickness of the coating on at least one point on the surface of the device is between about 0.2-10 microns.
12. The device of claim 1, wherein the medical device is selected from the group consisting of stents, stent grafts, vascular grafts, catheters, guide wires, balloons, filters, cerebral aneurysm filler coils, intraluminal paving systems, sutures, staples, anastomosis devices, vertebral disks, bone pins, suture anchors, hemostatic barriers, clamps, screws, plates, clips, slings, vascular implants, tissue adhesives and sealants, tissue scaffolds, myocardial plugs, pacemaker leads, valves, abdominal aortic aneurysm (AAA) grafts, embolic coils, various types of dressings, bone substitutes, intraluminal devices, and vascular supports.
13. The device of claim 1, wherein the frame is selected from the group consisting of stainless steel, nitinol, tantalum, a nonmagnetic nickel-cobalt-chromium-molybdenum [MP35N] alloy, platinum, titanium, a suitable biocompatible alloy, a suitable biocompatible material, and a combination thereof.
14. A medical device comprising a frame and a coating, the coating comprising about 1:1 to about 1:20 weight ratio taxane therapeutic agent to zein or modified zein admixed with levulinic acid.
15. The device of claim 14, wherein the coating comprises about 0.01 to about 1.5  $\mu\text{g}$  of taxane therapeutic agent per  $\text{mm}^2$  of the frame.
16. The device of claim 14, wherein the coating comprises about 0.3 to about 1.0  $\mu\text{g}$  of therapeutic agent per  $\text{mm}^2$  of the frame.
17. The device of claim 14, wherein the medical device is selected from the group consisting of stents, stent grafts, vascular grafts, catheters, guide wires,

balloons, filters, cerebral aneurysm filler coils, intraluminal paving systems, sutures, staples, anastomosis devices, vertebral disks, bone pins, suture anchors, hemostatic barriers, clamps, screws, plates, clips, slings, vascular implants, tissue adhesives and sealants, tissue scaffolds, myocardial plugs, pacemaker leads, valves, abdominal aortic aneurysm (AAA) grafts, embolic coils, various types of dressings, bone substitutes, intraluminal devices, and vascular supports.

18. The device of claim 14, wherein the medical device is a vascular stent.

19. The device of claim 14, wherein the therapeutic agent is paclitaxel or a paclitaxel derivative.

20. A method of delivering a therapeutic agent to a patient in need thereof comprising the steps of providing a medical device and implanting the medical device in a patient wherein the medical device comprises at least one therapeutic agent and zein admixed with levulinic acid with a ratio of about 1:1 to about 1:20 by weight of the at least one therapeutic agent to zein admixed with levulinic acid.




Figure 1




Figure 2




Figure 3A




Figure 3B




Figure 3C




Figure 3D




Figure 4




Figure 5




Figure 6




Figure 7